Impact of the European Randomized Study of Screening for Prostate Cancer ( ERSPC) on prostate-specific antigen ( PSA) testing by Dutch general practitioners.

Autor: Meer, Saskia, Kollen, Boudewijn J., Hirdes, Willem H., Steffens, Martijn G., Hoekstra‐Weebers, Josette E.H.M., Nijman, Rien M., Blanker, Marco H.
Předmět:
Zdroj: BJU International; Jul2013, Vol. 112 Issue 1, p26-31, 6p, 4 Charts, 1 Graph
Abstrakt: Objective To determine the impact of the European Randomized Study of Screening for Prostate Cancer ( ERSPC) publication in 2009 on prostate-specific antigen ( PSA) level testing by Dutch general practitioners (GPs) in men aged ≥40 years., Materials and Methods Retrospective study with a Dutch insurance company database (containing PSA test claims) and a large district hospital-laboratory database (containing PSA-test results)., The difference in primary PSA-testing rate as well as follow-up testing before and after the ERSPC was tested using the chi-square test with statistical significance at P < 0.05., Results Decline in PSA tests 4 months after ERSPC publication, especially for men aged ≥60 years., Primary testing as well as follow-up testing decreased, both for PSA levels of <4 ng/mL as well as for PSA levels of 4-10 ng/mL., Follow-up testing after a PSA level result of >10 ng/mL moderately increased ( P = 0.171)., Referral to a urologist after a PSA level result of >4 ng/mL decreased slightly after the ERSPC publication ( P = 0.044)., Conclusions After the ERSPC publication primary PSA testing as well as follow-up testing decreased., Follow-up testing seemed not to be adequate after an abnormal PSA result. The reasons for this remain unclear. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje